Immune cells retrained to hunt ovarian cancer in new trial

NCT ID NCT05225363

Recruiting now Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This phase 1 trial investigates a new treatment for advanced ovarian cancer that has stopped responding to platinum chemotherapy. The therapy uses a patient's own immune cells, called T cells, which are genetically modified in a lab to recognize and attack a protein called TAG72 found on cancer cells. The study aims to determine the safest dose and evaluate side effects in up to 33 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TAG72-CAR T cells
What this could lead to: If successful, this approach could offer a new treatment option for patients with platinum-resistant ovarian cancer by harnessing the immune system to target cancer cells.
What could go wrong: This is an early phase 1 trial focused on safety and dosing, so it is not yet known if the treatment will be effective. There are risks of side effects from the CAR T cells and the chemotherapy used in the regimen.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLATINUM-RESISTANT OVARIAN CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLATINUM-RESISTANT OVARIAN CARCINOMA

Contacts and locations

Locations

City of Hope Medical Center
RECRUITING

Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.